Therapeutic approaches for prion disorders

References

• Vana K, Zuber C, Nikles D, Weiss S. Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy. Cell. Mol. Neurobiol.27(1), 107–128 (2007).
   PubMed Web of Science ®Google Scholar
• Ladogana A, Puopolo M, Croes EA et al. Mortality from Creutzfeldt–Jakob disease and related disorders in Europe, Australia, and Canada. Neurology64(9), 1586–1591 (2005).
   PubMed Web of Science ®Google Scholar
• Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt–Jakob disease in the UK. Lancet347(9006), 921–925 (1996).
   PubMed Web of Science ®Google Scholar
• Will RG, Cousens SN, Farrington CP, Smith PG, Knight RS, Ironside JW. Deaths from variant Creutzfeldt–Jakob disease. Lancet353(9157), 979 (1999).
   PubMed Web of Science ®Google Scholar
• Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science302(5646), 871–874 (2003).
   PubMed Web of Science ®Google Scholar
• Mallucci GR, White MD, Farmer M et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron53(3), 325–335 (2007).
   PubMed Web of Science ®Google Scholar
• Farquhar CF, Dickinson AG. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J. Gen. Virol.67(Pt 3), 463–473 (1986).
   PubMed Web of Science ®Google Scholar
• Gilch S, Winklhofer KF, Groschup MH et al. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J.20(15), 3957–3966 (2001).
   PubMed Web of Science ®Google Scholar
• Nunziante M, Kehler C, Maas E, Kassack MU, Groschup M, Schatzl HM. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. J. Cell. Sci.118(Pt 21), 4959–4973 (2005).
   PubMed Web of Science ®Google Scholar
• Gauczynski S, Nikles D, El-Gogo S et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J. Infect. Dis.194(5), 702–709 (2006).
   PubMed Web of Science ®Google Scholar
• Adjou KT, Simoneau S, Sales N et al. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J. Gen. Virol.84(Pt 9), 2595–2603 (2003).
   PubMed Web of Science ®Google Scholar
• Larramendy-Gozalo C, Barret A, Daudigeos E et al. Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases. J. Gen. Virol.88(Pt 3), 1062–1067 (2007).
   PubMed Web of Science ®Google Scholar
• Caughey B, Raymond GJ. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol.67(2), 643–650 (1993).
   PubMed Web of Science ®Google Scholar
• Farquhar C, Dickinson A, Bruce M. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet353(9147), 117 (1999).
   PubMed Web of Science ®Google Scholar
• Whittle IR, Knight RS, Will RG. Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt–Jakob disease. Acta Neurochir. (Wien)148(6), 677–679 (2006).
   PubMed Web of Science ®Google Scholar
• Todd NV, Morrow J, Doh-ura K et al. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt–Jakob disease. J. Infect.50(5), 394–396 (2005).
   PubMed Web of Science ®Google Scholar
• Cordeiro Y, Machado F, Juliano L et al. DNA converts cellular prion protein into the β-sheet conformation and inhibits prion peptide aggregation. J. Biol. Chem.276(52), 49400–49409 (2001).
   PubMed Web of Science ®Google Scholar
• Deleault NR, Geoghegan JC, Nishina K, Kascsak R, Williamson RA, Supattapone S. Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J. Biol. Chem.280(29), 26873–26879 (2005).
   PubMed Web of Science ®Google Scholar
• Nandi PK, Leclerc E. Polymerization of murine recombinant prion protein in nucleic acid solution. Arch. Virol.144(9), 1751–1763 (1999).
   PubMed Web of Science ®Google Scholar
• Kocisko DA, Vaillant A, Lee KS et al. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob. Agents Chemother.50(3), 1034–1044 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen AS, Calkins E, Levene CI. Studies on experimental amyloidosis. I. Analysis of histology and staining reactions of casein-induced amyloidosis in the rabbit. Am. J. Pathol.35, 971–989 (1959).
   PubMed Web of Science ®Google Scholar
• Glenner GG. Amyloid deposits and amyloidosis: the b-fibrilloses (second of two parts). N. Engl. J. Med.302(24), 1333–1343 (1980).
   PubMed Web of Science ®Google Scholar
• Caughey B, Race RE. Potent inhibition of scrapie-associated PrP accumulation by congo red. J. Neurochem.59(2), 768–771 (1992).
   PubMed Web of Science ®Google Scholar
• Caspi S, Halimi M, Yanai A, Sasson SB, Taraboulos A, Gabizon R. The anti-prion activity of Congo red. Putative mechanism. J. Biol. Chem.273(6), 3484–3489 (1998).
   PubMed Web of Science ®Google Scholar
• Ingrosso L, Ladogana A, Pocchiari M. Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol.69(1), 506–508 (1995).
   PubMed Web of Science ®Google Scholar
• Bos RP, Koopman JP, Theuws JLG, Henderson PT. The essential role of the intestinal flora in the toxification of orally-administered benzidine-dyes: internal exposure of rats to benzidine after intestinal azo reduction. Mutat. Res.181, 327 (1987).
   Google Scholar
• Rudyk H, Vasiljevic S, Hennion RM, Birkett CR, Hope J, Gilbert IH. Screening Congo red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. J. Gen. Virol.81(Pt 4), 1155–1164 (2000).
   PubMed Web of Science ®Google Scholar
• Poli G, Martino PA, Villa S et al. Evaluation of anti-prion activity of Congo red and its derivatives in experimentally infected hamsters. Arzneimittelforschung54(7), 406–415 (2004).
   PubMed Web of Science ®Google Scholar
• Adjou KT, Demaimay R, Lasmezas C, Deslys JP, Seman M, Dormont D. MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Antimicrob. Agents Chemother.39(12), 2810–2812 (1995).
   PubMed Web of Science ®Google Scholar
• Pocchiari M, Schmittinger S, Masullo C. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J. Gen. Virol.68(Pt 1), 219–223 (1987).
   PubMed Web of Science ®Google Scholar
• Adjou KT, Demaimay R, Lasmezas CI, Seman M, Deslys JP, Dormont D. Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Res. Virol.147(4), 213–218 (1996).
   PubMedGoogle Scholar
• Demaimay R, Adjou KT, Beringue V et al. Late treatment with polyene antibiotics can prolong the survival time of scrapie-infected animals. J. Virol.71(12), 9685–9689 (1997).
   PubMed Web of Science ®Google Scholar
• Bolard J. Interaction of polyene antibiotics with membrane lipids: physicochemical studies of the molecular basis of selectivity. Drugs Exp. Clin. Res.12(6–7), 613–618 (1986).
   PubMedGoogle Scholar
• Beringue V, Lasmezas CI, Adjou KT et al. Inhibiting scrapie neuroinvasion by polyene antibiotic treatment of SCID mice. J. Gen. Virol.80(Pt 7), 1873–1877 (1999).
   PubMed Web of Science ®Google Scholar
• Hartsel SC, Weiland TR. Amphotericin B binds to amyloid fibrils and delays their formation: a therapeutic mechanism? Biochemistry42(20), 6228–6233 (2003).
   PubMed Web of Science ®Google Scholar
• Marella M, Lehmann S, Grassi J, Chabry J. Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release. J. Biol. Chem.277(28), 25457–25464 (2002).
   PubMed Web of Science ®Google Scholar
• Tagliavini F, Forloni G, Colombo L et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J. Mol. Biol.300(5), 1309–1322 (2000).
   PubMed Web of Science ®Google Scholar
• Forloni G, Iussich S, Awan T et al. Tetracyclines affect prion infectivity. Proc. Natl Acad. Sci. USA99(16), 10849–10854 (2002).
   PubMed Web of Science ®Google Scholar
• Caughey WS, Raymond LD, Horiuchi M, Caughey B. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc. Natl Acad. Sci. USA95(21), 12117–12122 (1998).
   PubMed Web of Science ®Google Scholar
• Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science287(5457), 1503–1506 (2000).
   PubMed Web of Science ®Google Scholar
• Priola SA, Raines A, Caughey W. Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. J. Infect. Dis.188(5), 699–705 (2003).
   PubMed Web of Science ®Google Scholar
• Kocisko DA, Caughey WS, Race RE, Roper G, Caughey B, Morrey JD. A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob. Agents Chemother.50(2), 759–761 (2006).
   PubMed Web of Science ®Google Scholar
• Supattapone S, Nguyen HO, Cohen FE, Prusiner SB, Scott MR. Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl Acad. Sci. USA96(25), 14529–14534 (1999).
   PubMed Web of Science ®Google Scholar
• Winklhofer KF, Tatzelt J. Cationic lipopolyamines induce degradation of PrPSc in scrapie-infected mouse neuroblastoma cells. Biol. Chem.381(5–6), 463–469 (2000).
   PubMed Web of Science ®Google Scholar
• Bera A, Nandi PK. Biological polyamines inhibit nucleic-acid-induced polymerisation of prion protein. Arch. Virol.152(4), 655–668 (2007).
   PubMed Web of Science ®Google Scholar
• Deleault NR, Lucassen RW, Supattapone S. RNA molecules stimulate prion protein conversion. Nature425(6959), 717–720 (2003).
   PubMed Web of Science ®Google Scholar
• Deleault NR, Harris BT, Rees JR, Supattapone S. Formation of native prions from minimal components in vitro. Proc. Natl Acad. Sci. USA104(23), 9741–9746 (2007).
   PubMed Web of Science ®Google Scholar
• Merlini G, Ascari E, Amboldi N et al. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc. Natl Acad. Sci. USA92(7), 2959–2963 (1995).
   PubMed Web of Science ®Google Scholar
• Tagliavini F, McArthur RA, Canciani B et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science276(5315), 1119–1122 (1997).
   PubMed Web of Science ®Google Scholar
• Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl Acad. Sci. USA98(17), 9836–9841 (2001).
   PubMed Web of Science ®Google Scholar
• Ryou C, Legname G, Peretz D, Craig JC, Baldwin MA, Prusiner SB. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab. Invest.83(6), 837–843 (2003).
   PubMed Web of Science ®Google Scholar
• Doh-ura K, Ishikawa K, Murakami-Kubo I et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J. Virol.78(10), 4999–5006 (2004).
   PubMed Web of Science ®Google Scholar
• Barret A, Tagliavini F, Forloni G et al. Evaluation of quinacrine treatment for prion diseases. J. Virol.77(15), 8462–9 (2003).
   PubMed Web of Science ®Google Scholar
• Soto C, Kascsak RJ, Saborio GP et al. Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet355(9199), 192–197 (2000).
   PubMed Web of Science ®Google Scholar
• Weiss S, Proske D, Neumann M et al. RNA aptamers specifically interact with the prion protein PrP. J. Virol.71(11), 8790–8797 (1997).
   PubMed Web of Science ®Google Scholar
• Proske D, Gilch S, Wopfner F, Schatzl HM, Winnacker EL, Famulok M. Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem3(8), 717–725 (2002).
   PubMed Web of Science ®Google Scholar
• Ertmer A, Gilch S, Yun SW et al. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J. Biol. Chem.279(40), 41918–41927 (2004).
   PubMed Web of Science ®Google Scholar
• Korth C, Stierli B, Streit P et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature390(6655), 74–77 (1997).
   PubMed Web of Science ®Google Scholar
• Feraudet C, Morel N, Simon S et al. Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J. Biol. Chem.280(12), 11247–11258 (2005).
   PubMed Web of Science ®Google Scholar
• Morel E, Andrieu T, Casagrande F et al. Bovine prion is endocytosed by human enterocytes via the 37 kDa/67 kDa laminin receptor. Am. J. Pathol.167(4), 1033–1042 (2005).
   PubMed Web of Science ®Google Scholar
• Paramithiotis E, Pinard M, Lawton T et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med.9(7), 893–899 (2003).
   PubMed Web of Science ®Google Scholar
• Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl Acad. Sci. USA98(16), 9295–9299 (2001).
   PubMed Web of Science ®Google Scholar
• Peretz D, Williamson RA, Kaneko K et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature412(6848), 739–743 (2001).
   PubMed Web of Science ®Google Scholar
• Flechsig E, Shmerling D, Hegyi I et al. Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron27(2), 399–408 (2000).
   PubMed Web of Science ®Google Scholar
• Kim CL, Karino A, Ishiguro N, Shinagawa M, Sato M, Horiuchi M. Cell-surface retention of PrPc by anti-PrP antibody prevents protease-resistant PrP formation. J. Gen. Virol.85(Pt 11), 3473–3482 (2004).
   PubMed Web of Science ®Google Scholar
• Perrier V, Solassol J, Crozet C et al. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPc degradation. J. Neurochem.89(2), 454–463 (2004).
   PubMed Web of Science ®Google Scholar
• Gilch S, Wopfner F, Renner-Muller I et al. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem.278(20), 18524–18531 (2003).
   PubMed Web of Science ®Google Scholar
• Moroncini G, Kanu N, Solforosi L et al. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. Proc. Natl Acad. Sci. USA101(28), 10404–10409 (2004).
   PubMed Web of Science ®Google Scholar
• Heppner FL, Musahl C, Arrighi I et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science294(5540), 178–182 (2001).
   PubMed Web of Science ®Google Scholar
• White AR, Enever P, Tayebi M et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature422(6927), 80–83 (2003).
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Sy MS, Li R et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett.336(3), 185–187 (2003).
   PubMed Web of Science ®Google Scholar
• Hundt C, Peyrin JM, Haik S et al. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J.20(21), 5876–5886 (2001).
   PubMed Web of Science ®Google Scholar
• Gauczynski S, Peyrin JM, Haik S et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J.20(21), 5863–5875 (2001).
   PubMed Web of Science ®Google Scholar
• Leucht C, Simoneau S, Rey C et al. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep.4(3), 290–295 (2003).
   PubMed Web of Science ®Google Scholar
• Zuber C, Knackmuss S, Rey C et al. Single chain Fv antibodies directed against the 37kDa/ 67kDa laminin receptor as therapeutic tools in prion diseases. Mol. Immunol. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Pankiewicz J, Prelli F, Sy MS et al. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur. J. Neurosci.23(10), 2635–2647 (2006).
   PubMed Web of Science ®Google Scholar
• Solforosi L, Criado JR, McGavern DB et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science303(5663), 1514–1516 (2004).
   PubMed Web of Science ®Google Scholar
• Adamson CS, Yao Y, Vasiljevic S, Sy MS, Ren J, Jones IM. Novel single chain antibodies to the prion protein identified by phage display. Virology358(1), 166–177 (2007).
   PubMed Web of Science ®Google Scholar
• Leclerc E, Liemann S, Wildegger G, Vetter SW, Nilsson F. Selection and characterization of single chain Fv fragments against murine recombinant prion protein from a synthetic human antibody phage display library. Hum. Antibodies9(4), 207–214 (2000).
   PubMedGoogle Scholar
• Donofrio G, Heppner FL, Polymenidou M, Musahl C, Aguzzi A. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J. Virol.79(13), 8330–8338 (2005).
   PubMed Web of Science ®Google Scholar
• Vetrugno V, Cardinale A, Filesi I et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem. Biophys. Res. Commun.338(4), 1791–1797 (2005).
   PubMed Web of Science ®Google Scholar
• Buchholz CJ, Bach P, Nikles D, Kalinke U. Prion protein-specific antibodies for therapeutic intervention of transmissible spongiform encephalopathies. Expert Opin. Biol. Ther.6(3), 293–300 (2006).
   PubMed Web of Science ®Google Scholar
• Polymenidou M, Heppner FL, Pellicioli EC et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl Acad. Sci. USA101(Suppl. 2), 14670–14676 (2004).
   PubMed Web of Science ®Google Scholar
• Nikles D, Bach P, Boller K et al. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J. Virol.79(7), 4033–4042 (2005).
   PubMed Web of Science ®Google Scholar
• Goni F, Knudsen E, Schreiber F et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience133(2), 413–421 (2005).
   PubMed Web of Science ®Google Scholar
• Fernandez-Borges N, Brun A, Whitton JL et al. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J. Virol.80(20), 9970–9976 (2006).
   PubMed Web of Science ®Google Scholar
• Handisurya A, Gilch S, Winter D et al. Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. FEBS J.274(7), 1747–1758 (2007).
   PubMed Web of Science ®Google Scholar
• Pillon JL, Loiacono CM, Okeson D et al. Early Success in the development of a PrPSc vaccine using a mouse model system. Presented at: Prion 2006 Conference (Strategies, Advances and Trends Towards Protection of Society). Torino, Italy, 3–6 October 2006.
   Google Scholar
• Mathiason CK, Powers JG, Dahmes SJ et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science314(5796), 133–136 (2006).
   PubMed Web of Science ®Google Scholar
• Priola SA, Caughey B. Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis. Mol. Neurobiol.8(2–3), 113–120 (1994).
   PubMed Web of Science ®Google Scholar
• Kaneko K, Zulianello L, Scott M et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl Acad. Sci. USA94(19), 10069–10074 (1997).
   PubMed Web of Science ®Google Scholar
• Hölscher C, Delius H, Bürkle A. Overexpression of nonconvertible PrPc δ114–121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc) accumulation. J. Virol.72(2), 1153–1159 (1998).
   PubMed Web of Science ®Google Scholar
• Perrier V, Kaneko K, Safar J et al. Dominant-negative inhibition of prion replication in transgenic mice. Proc. Natl Acad. Sci. USA99(20), 13079–13084 (2002).
   PubMed Web of Science ®Google Scholar
• Furuya K, Kawahara N, Yamakawa Y et al. Intracerebroventricular delivery of dominant negative prion protein in a mouse model of iatrogenic Creutzfeldt–Jakob disease after dura graft transplantation. Neurosci. Lett.402(3), 222–226 (2006).
   PubMed Web of Science ®Google Scholar
• Crozet C, Lin YL, Mettling C et al. Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations. J. Cell. Sci.117(Pt 23), 5591–5597 (2004).
   PubMed Web of Science ®Google Scholar
• Bueler H, Aguzzi A, Sailer A et al. Mice devoid of PrP are resistant to scrapie. Cell73(7), 1339–1347 (1993).
   PubMed Web of Science ®Google Scholar
• Vana K, Weiss S. A trans-dominant negative 37kDa/67kDa laminin receptor mutant impairs PrP(Sc) propagation in scrapie-infected neuronal cells. J. Mol. Biol.358(1), 57–66 (2006).
   PubMed Web of Science ®Google Scholar
• Daude N, Marella M, Chabry J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J. Cell. Sci.116(Pt 13), 2775–2779 (2003).
   PubMed Web of Science ®Google Scholar
• Golding MC, Long CR, Carmell MA, Hannon GJ, Westhusin ME. Suppression of prion protein in livestock by RNA interference. Proc. Natl Acad. Sci. USA103(14), 5285–5290 (2006).
   PubMed Web of Science ®Google Scholar
• Pfeifer A, Eigenbrod S, Al-Khadra S et al. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J. Clin. Invest.116(12), 3204–3210 (2006).
   PubMed Web of Science ®Google Scholar
• Bueler H, Fischer M, Lang Y et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature356(6370), 577–582 (1992).
   PubMed Web of Science ®Google Scholar
• Richt JA, Kasinathan P, Hamir AN et al. Production of cattle lacking prion protein. Nat. Biotechnol.25(1), 132–8 (2007).
   PubMed Web of Science ®Google Scholar
• Leucht C, Vana K, Renner-Muller I et al. Knock-down of the 37-kDa/67-kDa laminin receptor in mouse brain by transgenic expression of specific antisense LRP RNA. Transgenic Res.13(1), 81–85 (2004).
   PubMed Web of Science ®Google Scholar
• Rieger R, Edenhofer F, Lasmezas CI, Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat. Med.3(12), 1383–1388 (1997).
   PubMed Web of Science ®Google Scholar
• Zuber C, Ludewigs H, Weiss S. Therapeutic approaches targeting the prion receptor LRP/LR. Vet. Microbiol.123, 387–393 (2007).
   PubMed Web of Science ®Google Scholar
• Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain129, 2241–2265 (2006).
   PubMed Web of Science ®Google Scholar
• Gresser I, Maury C, Chandler RL. Failure to modify scrapie in mice by administration of interferon or anti-interferon globulin. J. Gen. Virol.64, 1387–1389 (1983).
   PubMed Web of Science ®Google Scholar
• Grigoriev V, Adjou KT, Sales N et al. Effects of the polyene antibiotic derivative MS-8209 on the astrocyte lysosomal system of scrapie-infected hamsters. J. Mol. Neurosci.18, 271–281 (2002).
   PubMed Web of Science ®Google Scholar
• Terzano MG, Montanari E, Calzetti S, Mancia D, Lechi A. The effect of amantadine on arousal and EEG patterns in Creutzfeldt–Jakob disease. Arch. Neurol.40(9), 555–559 (1983).
   PubMedGoogle Scholar
• Dealler S, Rainov N. Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease. I. Drugs6, 470–478 (2003).
   PubMedGoogle Scholar
• Parry A, Baker I, Stacey R, Wimalaratna S. Long term survival in a patient with variant Creutzfeldt–Jakob disease treated with intraventricular pentosan polysulphate. J. Neurol. Neurosurg. Psychiatry78(7), 733–734 (2007).
   PubMed Web of Science ®Google Scholar
• Farquard C. Sodium pentosan polysulfate use in rodent models of Scrapie and BSE. Oral presentation at: Prion 2006 Conference (Strategies, Advances and Trends Towards Protection of Society). Torino, Italy, 3–6 October 2006.
   Google Scholar
• Otto M, Cepek L, Ratzka P et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology62, 714–718 (2004).
   PubMed Web of Science ®Google Scholar
• Haik S, Brandel JP, Salomon D et al. Compassionate use of quinacrine in Creutzfeldt–Jakob disease fails to show significant effects. Neurology63(12), 2413–2415 (2004).
   PubMed Web of Science ®Google Scholar
• Forloni G, Colombo L, Girola L, Tagliavini F, Salamona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett.487(3), 404–407 (2001).
   PubMed Web of Science ®Google Scholar
• Tagliavini F. Prion disease therapeutics: Tetracyclic compounds in in vitro models, animal models and patients with Creutzfeldt–Jakob Disease. Oral presentation at: 6th National TSE-Forschungsplattform Congress. Greifswald, Germany, 26–28 June 2007.
   Google Scholar
• Parchi P, Giese A, Capellari S et al. Classification of sporadic Creutzfeldt–Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann. Neurol.46, 224–233 (1999).
   PubMed Web of Science ®Google Scholar
• Heinemann U, Krasnianski A, Meissner B et al. Creutzfeldt–Jakob disease in Germany: a prospective 12-years surveillance. Brain130, 1350–1359 (2007).
   PubMed Web of Science ®Google Scholar
• Zerr I, Schulz-Schaeffer WJ, Giese A et al. Current clinical diagnosis in CJD: identification of uncommon variants. Ann. Neurol.48, 323–329 (2000).
   PubMed Web of Science ®Google Scholar
• Sanchez-Juan P, Green A, Ladogana A et al. Cerebrospinal fluid tests in the differential diagnosis of CJD. Neurology67(4), 637–643 (2006).
   PubMed Web of Science ®Google Scholar
• Tschampa HJ, Kallenberg K, Urbach H et al. MRI in the diagnosis of sporadic Creutzfeldt–Jakob disease: a study on inter-observer agreement. Brain128(Pt 9), 2026–2033 (2005).
   PubMed Web of Science ®Google Scholar
• Pocchiari M, Poupolo M, Croes EA et al. Predictors of survival in sporadic Creutzfeldt–Jakob disease and other human transmissible spongiform encephalopathies. Brain10, 2348–2359 (2004).
   Google Scholar
• Cordery RJ, Hall M, Cipolotti L et al. Early cognitive decline in Creutzfeldt–Jakob disease associated with human growth hormone treatment. J. Neurol. Neurosurg. Psychiatry74, 1412–1416 (2003).
   PubMed Web of Science ®Google Scholar
• Cordery RJ, Alner K, Cipolotti L et al. The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease. J. Neurol. Neurosurg. Psychiatry76, 330–336 (2005).
   PubMed Web of Science ®Google Scholar
• Hamaguchi T, Kitamoto T, Sato T et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt–Jakob disease. Neurology64, 643–8 (2005).
   PubMed Web of Science ®Google Scholar
• Zerr I, Poser S. Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests. APMIS110, 88–98 (2002).
   PubMed Web of Science ®Google Scholar
• Brown P, Gibbs CJ Jr, Rodgers-Johnson P et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann. Neurol.35(5), 513–529 (1994).
   PubMed Web of Science ®Google Scholar
• Otto A, Zerr I, Lantsch M, Weidehaas K, Riedemann C, Poser S. Akinetic mutism as a classification criterion for the diagnosis of Creutzfeldt–Jakob disease. J. Neurol. Neurosurg. Psychiatry64(4), 524–528 (1998).
   PubMed Web of Science ®Google Scholar
• Krasnianski A, Meissner B, Schulz-Schaeffer W et al. Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt–Jakob disease. Arch. Neurol.63(6), 876–880 (2006).
   PubMedGoogle Scholar
• Krasnianski A, Schulz-Schaeffer WJ, Kallenberg K et al. Clinical findings and diagnostic tests in the MV-2 subtype of sporadic CJD. Brain129, 2288–2296 (2006).
   PubMed Web of Science ®Google Scholar
• Meissner B, Westner I, Kallenberg K et al. Sporadic Creutzfeldt–Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology65(10), 1544–1550 (2005).
   PubMed Web of Science ®Google Scholar
• de Silva R. Human spongiform encephalopathy. In: Prion Diseases. Baker HF, Ridley RM (Eds). Humana Press, NJ, USA 15–33 (1996).
   Google Scholar
• Haïk S, Brandel JP, Sazdovitch V et al. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt–Jakob disease. Neurology55, 1401–1404 (2000).
   PubMed Web of Science ®Google Scholar
• Poser S, Mollenhauer B, Krauss A et al. How to improve the clinical diagnosis of Creutzfeldt–Jakob disease. Brain122, 2345–2351 (1999).
   PubMed Web of Science ®Google Scholar
• Tschampa HJ, Neumann M, Zerr I et al. Patients with Alzheimer’s disease and dementia with Lewy bodies mistaken for Creutzfeldt–Jakob disease. J. Neurol. Neurosurg. Psychiatry71, 33–39 (2001).
   PubMed Web of Science ®Google Scholar
• Van Everbroeck B, Dobbeleir I, De Waele M, De Deyn P, Martin J-J, Cras P. Differential diagnosis of 201 possible Creutzfeldt–Jakob disease patients. J. Neurol.251, 298–304 (2004).
   PubMed Web of Science ®Google Scholar
• Boesenberg C, Schulz-Schaeffer WJ, Meissner B et al. Clinical course in young patients with sporadic Creutzfeldt–Jakob disease. Ann. Neurol.58, 533–543 (2005).
   PubMed Web of Science ®Google Scholar
• Ladogana A, Puopolo M, Croes EA et al. Mortality from Creutzfeldt–Jakob disease and related disorders in Europe, Australia, and Canada. Neurology64, 1586–1591 (2005).
   PubMed Web of Science ®Google Scholar
• Braaten AJ, Parsons TD, McCue R, Sellers A, Burns WJ. Neurocognitive differential diagnosis of dementing diseases: Alzheimer's dementia, vascular dementia, frontotemporal dementia, and major depressive disorder. Int. J. Neurosci.116(11), 1271–1293 (2006).
   PubMed Web of Science ®Google Scholar
• Doh-ura K. Pentosan polysulfate and amyloidophilic chemicals for prion diseases. Presented at: Prion 2006 Conference (Strategies, Advances and Trends Towards Protection of Society). Torino, Italy, 3–6 October 2006.
   Google Scholar
• Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. NMR structure of the mouse prion protein domain PrP(121–321). Nature382(6587), 180–182 (1996).
   PubMed Web of Science ®Google Scholar
• Supattapone S, Wille H, Uyechi L et al. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol.75(7), 3453–3461 (2001).
   PubMed Web of Science ®Google Scholar
• Beringue V, Vilette D, Mallinson G et al. PrPSc binding antibodies are potent inhibitors of prion replication in cell lines. J. Biol. Chem.279(38), 39671–39676 (2004).
   PubMed Web of Science ®Google Scholar
• David AS, Grant R, Ballantyne JP. Unsuccessful treatment of Creutzfeldt–Jakob disease with acyclovir [letter]. Lancet1(8375), 512–513 (1984).
   PubMed Web of Science ®Google Scholar
• Newman PK. Acyclovir in Creutzfeldt–Jakob disease [letter]. Lancet1(8380), 793 (1984).
   PubMed Web of Science ®Google Scholar
• Braham J. Amantadine in the treatment of Creutzfeldt–Jakob disease [letter]. Arch. Neurol.41(6), 585–586 (1984).
   PubMedGoogle Scholar
• Ratcliffe J, Rittman A, Wolf S, Verity MA. Creutzfeldt–Jakob disease with focal onset unsuccessfully treated with amantadine. Bull. Los Angeles Neurol. Soc.40(1), 18–20 (1975).
   PubMedGoogle Scholar
• Terzano MG, Mancia D, Manzoni GC. Periodic activities in Creutzfeldt–Jakob disease and epilepsy. Prog. Clin. Biol. Res.124(199), 199–226 (1983).
   PubMedGoogle Scholar
• Braham J. Jakob-Creutzfeldt disease: treatment by amantadine. Br. Med. J.4, 212–213 (1971).
   PubMedGoogle Scholar
• Sanders WL. Creutzfeldt–Jakob disease treated with amantadine. J. Neurol. Neurosurg. Psychiatry42(10), 960–961 (1979).
   PubMed Web of Science ®Google Scholar
• Sanders WL, Dunn TL. Creutzfeldt–Jakob disease treated with amantidine. A report of two cases. J. Neurol. Neurosurg. Psychiatry36(4), 581–584 (1973).
   PubMed Web of Science ®Google Scholar
• Masullo C, Macchi G, Xi YG, Pocchiari M. Failure to ameliorate Creutzfeldt–Jakob disease with amphotericin B therapy [letter]. J. Infect. Dis.165(4), 784–785 (1992).
   PubMed Web of Science ®Google Scholar
• Kovanen J, Haltia M, Cantell K. Failure of interferon to modify Creutzfeldt–Jakob disease. Br. Med. J.280, 902 (1980).
   PubMedGoogle Scholar
• Nakajima M, Yamada T, Kusuhara T et al. Results of quinacrine administration to patients with Creutzfeldt–Jakob disease. Dement. Geriatr. Cogn. Disord.17, 158–163 (2004).
   PubMed Web of Science ®Google Scholar
• Benito-Leon J. Compassionate use of quinacrine in Creutzfeldt–Jakob disease fails to show significant effects. Neurology64(10), 1824 (2005).
   PubMedGoogle Scholar
• Satoh K, Shirabe S, Eguchi K et al. Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt–Jakob disease. Cell. Mol. Neurobiol.24(6), 873–875 (2004).
   PubMed Web of Science ®Google Scholar
• Scoaazec JY, Krolak-Salmon P, Casez O et al. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt–Jakob disease. Ann. Neurol.53(4), 546–547 (2003).
   Google Scholar
• Furlow TJ, Whitley RJ, Wilmes FJ. Repeated suppression of Creutzfeldt–Jakob disease with vidarabine [letter]. Lancet2(8297), 564–565 (1982).
   PubMedGoogle Scholar